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ABSTRACT 
Recently, the interest in functional foods is increased dramatically thanks to some scientific evidences demonstrating 
that, regardless of their nutritional value, some foods components beneficially influence several functions of the body, 
making them “functional” for the prevention and treatment of degenerative diseases, such as type 2 diabetes and car-
diovascular diseases. In particular, the marketplace offers conventional and modified functional foods which acting on 
intestine, glucose and lipid metabolism are potentially useful for diabetic patients. The field of functional foods, how-
ever, presents some criticalities. Up to now, only few functional foods have obtained the statement of a “Health Claim”, 
either because there are not sufficient scientific evidences based on human intervention studies, that justify a “Health 
Claim”, or because data are not consistent with the proposed claims. In addition, some functional foods show a low pal-
atability and a lack of variety. Both these issues limit their ordinary intake. This critical aspect also involves the lack of 
a possible synergistic effect deriving from the contemporary consumption in the diet of different functional foods, as 
observed with some healthy dietary pattern. Functional foods represent, then, a challenge for the food industry, which 
needs to implement and/or develop innovative technologies able to create new foods with improved healthy properties, 
but also with better organoleptic properties suitable for a daily consumption. 
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1. Introduction 
The interest in functional foods has increased dramati- 
cally in the last two decades, especially in North America, 
thanks to their capacity in beneficially influencing meta- 
bolic parameters and chronic degenerative diseases such 
as type 2 diabetes (T2DM), cardiovascular disease (CVD) 
and some types of cancer [1].  
The results of several epidemiological and clinical 
studies indicate that the consumption of soft drinks, red 
meat, sausages, saturated and trans fats is closely associ-
ated with an increased risk of developing T2DM [2,3]. 
By contrast, the use of whole grains, legumes, fruit, 
vegetables, nuts, tea and coffee decreases that risk [4-6] 
(Table 1). It is also known that the combination of these 
types of food in a diet model such as the “Mediterranean 
diet”, or so-called “Prudent” diet, is even more effective 
in preventing T2DM than the consumption of the single 
food [1]. In fact, the food synergy of the Mediterranean 
diet maximizes the effect of all the mechanisms involved 
in the prevention of type 2 diabetes such as weight loss, 
improved insulin sensitivity, reduction of oxidative stress 
and of subclinical inflammation. We can therefore say 
that the consumption of those foods, associated with a 
lower risk of developing type 2 diabetes, allows not only 
the intake of nutrients essential for life, but also of other 
components (e.g., vegetable fiber, oligosaccharides, phy-
tosterols, oligo-mineral elements, vitamins and various 
molecules with antioxidant activity) capable of positively 
influencing several functions of the body, regardless of 
their nutritional value, making them “functional” for the 
prevention and treatment of T2DM. 
Over the past two decades, due to evidences of this 
type, the landscape of the food and nutrition field has 
changed constantly. Therefore, food is no longer solely 
viewed in terms of macro or micronutrients, but it is now 
a real way to achieve the so-called state of “wellness”. 
The possibility of other potential health promoting com- 
ponents found in foods has increased the interest in func- 
tional foods due not only to the results of scientific re- 
searches, which link the diet to the development of *Corresponding author. 
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Table 1. Foods, nutrients and dietary patterns associated with risk of developing type 2 diabetes. 
 Increased Risk  Degree of Evidence Decreased Risk Degree of Evidence 
Foods Soft Drinks ++ Whole Grains ++ 
 Red meat and processed meat ++ Tea and Coffee ++ 
 Oil and hydrogenated margarines + Milk and dairy products low in fat ++ 
 Eggs + Fruits, vegetables, legumes + 
   Moderate alcohol consumption + 
   Hazelnuts (women) + 
Nutrients Saturated fatty acids + Fibers ++ 
 Trans fatty acids + Unsaturated fatty acids ++ 
   Antioxidants + 
   Magnesium + 
Dietary Pattern High glycemic index ++ Low glycemic index + 
 Western Diet ++ Mediterranean Diet +++ 
   Diet low in fat +++ 
Degree of evidence from prospective epidemiological studies and clinical trials = +++ High; ++Moderate; + Reasonable. 
 
chronic diseases, but also to other factors, such as a 
greater attention of consumers to their health, the in- 
crease of health costs, the high competitiveness of the 
food marketplace, the new legislation governing food 
and the technology advancements such as biotechnology. 
Although several functional foods are available on the 
marketplace, only few have a “health claim” due to scant 
scientific evidence based on human intervention studies 
[7]. Functional foods represent a challenge for the food 
industry, which needs to implement and/or develop in- 
novative technologies able to create new foods with im- 
proved healthy properties, but also with better organolep- 
tic properties suitable for an everyday consumption.  
2. Definition of “Functional Food”  
In the United States the functional foods are not officially 
recognized as a regulatory category by the American 
Food and Drug Administration (FDA) [8]. Thus, the term 
functional food is currently a marketing rather than a 
regulatory idiom. 
Therefore there is not a universal and unambiguous 
definition of “functional food”, but several working defi- 
nitions have been put forward by various organizations, 
such as the American Dietetic Association (ADA) [9], 
the International Food Information Council (IFIC) [10] 
or the Institute of Food Technologists [11]. All these 
definitions, beyond small differences, specify, however, 
that a food to be considered “functional”, in addition to 
fulfil nutritional needs, must have further properties 
beneficial to the body. 
The European Commission Concerted Action on 
Functional Food Science in Europe (FUFOSE) regards a 
food as functional if it is satisfactorily demonstrated to 
affect beneficially one or more target functions of the 
body, in a way that it is relevant to an improved state of 
health and well-being and/or a reduction of disease risk, 
beyond adequate nutritional effects [12]. In this context, 
functional foods must demonstrate their effects with an 
ordinary intake normally expected to be consumed in a 
diet.  
This latter feature distinguishes the functional food 
from the nutraceutical food, with which it is often con- 
fused. Nutraceuticals exhibit, by definition, their effects 
in doses much higher than those usually assumed in a 
diet, i.e. pharmacological doses and not necessarily con- 
tained in the food [13]. 
As a matter of fact, having also become very popular 
in recent years, unlike functional foods, nutraceuticals 
are pharmaceutical preparations (tablets, capsules, pills, 
etc.) containing the physiologically active components 
naturally present in foods, but extracted, purified, con- 
centrated, and, therefore, undetectable. 
3. Functional Food Categories 
There are different types of “functional foods”, but basi- 
cally they can be divided into conventional and modified 
foods. Examples of conventional foods are those in 
which the components with positive effects are already 
naturally present, such as whole grains, nuts, soybean, 
tomatoes etc. Modified foods are those that have been  
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transformed by technology to obtain a functional food, 
by enriching or adding one or more components with 
beneficial effects, by removing one or more components 
with adverse effects from the food (e.g., allergenic pro-
teins, lactose-free milk), by replacing a component with 
another that has beneficial effects (e.g., fat replaced by 
HP inulin) or by improving the bioavailability of some 
molecules, which show potential health benefits.  
Whole grains represent a particularly interesting ex-
ample of conventional functional food. The most con-
sumed cereal in the world is certainly wheat, which is the 
main energy source in human nutrition. Wheat, as other 
cereals intended for human consumption, can be used 
either as whole or refined. 
In particular, consumers of whole grains have shown a 
lower risk of developing type 2 diabetes than those con-
suming refined grains [4]. In order to explain the mecha-
nisms that support this observation, it is necessary to 
fully understand what happens during the refining proc-
ess of the caryopsis, the structure of which is formed by 
the following three different layers: 
1) the external part, more commonly known as bran, is 
rich in fibres, group B vitamins, phytonutrients (fla-
vonoids, indoles), antioxidants, minerals and contains 
also a small amount of proteins; 
2) the central stratum, the most important from a nutri-
tional point of view, is the endosperm, which is rich 
in starch and proteins but poor in micronutrients; 
3) the inner part is represented by the embryo or germ, 
and contains a high amount of lipids and proteins, 
minerals (Fe, Zn), vitamins B group, phytosterols, an-
tioxidants and vitamin E [14]. 
During the refining process, the cereal is crushed and 
deprived of the bran and the germ to produce the 
so-called “refined grain flour.” When the bran and germ 
components are not removed, the flour obtained is de-
fined as “whole grain flour.” Refining process depletes 
the cereal by many nutrients and biologically active 
components such as fibres, oligosaccharides, vitamins, 
minerals, phytosterols, phytoestrogens, and polyphenols. 
In fact, refined grain flours contain about 78% less total 
fiber and over 50% less minerals and vitamins. As re-
gards the polyphenols, refined grain flour contains 91% 
less ferulic acid, 51% less betaine and 78% less alkilre-
sorcinol [15]. There are many experimental evidence 
showing that the components removed from the refining 
process are able to regulate different important functions 
of the body [14,15]. 
It is well known, in fact, that the vegetable fiber modu-
lates some digestive enzymes, reduces the absorption of 
fats and slows down the absorption of carbohydrates, 
with beneficial effects both on the lipid and glucose pro-
file. It also improves gut peristalsis and stimulates the 
selective growth of colonic bacterial flora, crucial for the 
production of short-chain fatty acids (SCFAs): acetate, 
propionate and butyrate. These molecules, by acting on 
different organs with multiple mechanisms, are capable 
of preserving the colonic mucosa, counteracting the sub-
clinical inflammation and improving insulin sensitivity. 
In addition, SCFAs, produced by bacterial flora, influ-
ence body fat stores by sending satiety signals to hypo-
thalamic nuclei, which regulate the sense of hunger and 
satiety, inhibiting the food intake. This mechanism con-
tributes to the prevention of overweight/obesity, an im-
portant risk factor for the T2DM and CVD [16]. 
The polyphenols, flavonoids, vitamins and some min-
erals, such as selenium and zinc, possess remarkable an-
tioxidant, chemo-preventive and also hormonal regula-
tion properties, as in the case of phytoestrogens [15]. 
Therefore, the lowest risk of developing T2DM, ob-
served in consumers of whole grains compared to those 
consuming refined grains, depends on the ability of the 
fibers, polyphenols, phytoestrogens, sterols and oligo- 
mineral elements to improve the insulin resistance, which 
represents the pathogenic factor of T2DM. Probably all 
these components act with different mechanisms giving 
rise to a synergistic effect. 
4. Food Technology Applied to Cereals:  
Advantages and Disadvantages 
Scientific evidence suggests that the refining of wheat is 
an example of food technology unfavourable to human 
health [17,18]. Therefore, the researchers’ interest, both 
in the medical field and in the field of food technology, 
has been stimulated to investigate the mechanisms of 
action by which the consumption of whole grains pro-
duces beneficial effects and to develop innovative tech-
niques, able to preserve, as much as possible, the func-
tional components of whole grain products. This concern 
has led to the implementation of a European project, 
HealthGrain, the purpose of which was to improve the 
nutritional value and health benefits of whole grains and 
to optimize their use in the diet. For this purpose, the 
organoleptic qualities of cereal-based foods have been 
studied and new technologies have been developed in 
order to obtain the production of cereal foods, that still 
contain the healthy components [19]. 
Within this project, for example, a less aggressive 
method for the peeling of the wheat caryopsis has been 
developed. This new peeling removes only the outermost 
layer of the pericarp and so the whole wheat flour ob-
tained has higher contents of folic acid, choline, tocols 
and alkilresorcinol than the traditional flour. This is an 
emblematic example of how technology is able to pre-
serve the functional components naturally present in ce-
reals [20]. 
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5. Functional Foods and Their Targets 
Functional foods may act on different targets; the largest 
segment of the marketplace for functional products in 
Europe, Japan and Australia is certainly represented by 
those which better the gut environment, but many are 
also those that act by improving glucose and lipid me-
tabolism. 
5.1. Intestine 
The interest for this type of functional foods in relation to 
metabolic diseases is growing because results of studies 
have shown that gut microbiota may influence metabo-
lism and body composition [21]. In particular, gut micro-
biota seems to be involved in the genesis of excessive 
adipose tissue development, chronic inflammation and 
insulin resistance [22,23]. 
This first category of functional foods includes pre-
biotics, probiotics and synbiotics. “Prebiotic” is a com-
ponent or a food ingredient which is fermented by the gut 
bacterial flora and is able to induce the selective growth 
of one or more bacterial strains, with positive effects on 
human health. “Probiotic” is a living and vital organism 
which, if ingested in sufficient quantities, has beneficial 
effects on human health. “Synbiotic” consists, instead, of 
a blend of prebiotics and probiotics, which improves the 
survival and engraftment of living microorganisms in-
gested in the gastrointestinal tract [24]. 
Prebiotics used in the food industry are polymers of 
fructose with glucosidic β (2→1) bonds that cannot be 
hydrolyzed by human digestive enzymes and, therefore, 
reach the colon undigested, where they are fermented by 
intestinal flora to short chain fatty acids. Prebiotics ac-
cording to their polymerization degree are classified into: 
Fructo-oligosaccharides (FOS), are a class of short 
chain polymers of fructose—consisting of one molecule 
of glucose and at least 2 of fructose (GFn), up to a maxi-
mum of 4 molecules (Degree polymerization, DP-4)— 
and are synthesized from sucrose; 
Oligofructose (OFS), is a polymer of fructose (Fn) 
containing a maximum of 10 units and is produced by the 
partial hydrolysis of inulin; 
Inulin is a polymer with a long chain (DP ≥ 10) which 
is obtained from various vegetal sources by aqueous ex-
traction and is not subjected to further processes (mixture 
of GFn and Fn); 
HP inulin, is a long chain polymer, with a high mo-
lecular weight, from which the polymers of fructose with 
DP < 10 units have been removed (mixture of GFn and 
Fn) [25]. 
FOS, OFS and inulin are water highly soluble, non- 
viscous, odourless and have approximately 30% to 50% 
of the sweetness of sucrose molecules. Thanks to these 
characteristics they can partially replace sucrose in food 
industry, particularly in baked products. HP inulin is 
characterized, on the other hand, by a low water solubil-
ity for which, when mixed with water or milk, it forms 
micro-crystals that impart a creamy appearance to the 
mixture; it can, therefore, substitute fat in the food indus-
try for the production of low fat spreads. 
There is a substantial scientific evidence about the fact 
that a daily consumption of 10 - 20 g of prebiotics in-
duces selective growth of Lactobacilli and Bifidobacteria, 
increases stool volume, raises the number of evacuations, 
stimulates the production of SCFAs and immunoglobulin 
synthesis [26]. Thus, the habitual consumption of pre-
biotics regularizes the bowel, increases gut resistance to 
infection by pathogenic bacteria, helps to prevent and 
treat gut inflammatory diseases and reduces the risk of 
developing colorectal cancer [27-30]. Further prebiotics 
consumption benefits are the increase in absorption of 
some minerals (Ca, Mg, Zn, Fe) and the enhancement of 
vitamin B synthesis [31]. The benefits of regular con-
sumption of prebiotics on insulin sensitivity are less clear. 
The experimental evidences in animal models suggest 
that the beneficial effect of prebiotics on insulin sensitiv-
ity and risk of type 2 diabetes is largely mediated by a 
reduced weight gain [32]. In fact, prebiotics are fer-
mented in the colon by intestinal bacteria with the pro-
duction of acetic, propionic and butyric acids and may 
influence body weight regulation by at least three proc-
esses: 1) by decreasing gastric emptying rate by SCFA, 
as demonstrated in animals and humans [33], thus in-
creasing the satiating effect of the meal; 2) by using the 
ability of propionate and acetate to reduce non esterified 
fatty acids (NEFA) plasma levels, responsible for pe-
ripheral and hepatic insulin resistance [34,35]; and fi-
nally, 3) by exploiting the ability of propionate to modu-
late glucose metabolism by increasing hepatic glycolysis 
and decreasing hepatic glucose production, as shown in 
isolated rat hepatocytes [36], as well as by stimulating 
Glucagon Like Peptide-1 (GLP-1) secretion [37]. 
At present, the consumption of functional foods en-
riched and/or added with prebiotics in the context of a 
healthy diet can, however, be recommended both to gen-
eral population and to patients with diabetes, on the basis 
of the beneficial effects on the gut, consistently demon-
strated in clinical trials and on the potential benefits in 
improving insulin resistance [38]. 
Probiotic is a living and vital organism, usually be-
longing to the group of lactic acid bacteria and bifido-
bacteria. The strains selection is based on the following 
characteristics: human intestinal environment; bile, acids 
enzymes and oxygen stability; ability of adhesion to the 
gut mucosa; aptitude to colonize the human gastrointestinal 
tract; production of antimicrobial substances and, finally, 
demonstrated efficacy and safety. Recently, the ability to 
ferment oligosaccharides, especially FOS (prebiotic), has 
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been considered as an additional criterion of selection. 
This ability may confer a competitive advantage against 
the gut microbial population. 
Probiotics are mainly added to yoghurt, fermented 
milks and cheeses, but other fortified foods, such as ice 
creams, spreads and meat products, are under investiga-
tion. A crucial aspect of functional foods based on probi-
otics, in the light of the labelling legislation and the con-
sumer information, concerns their capability to survive 
the technological processes and, in particular, the prepa-
ration and storage steps. Another important feature re-
gards the minimum number of probiotic cells that are 
useful for the food production. Effectively, the survival 
to the technological processes has been only sporadically 
considered, even if such a characteristic constitutes the 
limiting factor for the production of some commercial 
products. As for as cheese and fermented milks are con-
cerned, it is necessary to establish and ensure proper 
shelf life, which is a suitable interval within which the 
declared functional properties do not decrease below a 
predefined level of acceptability. 
In this respect, there is no comprehensive information 
regarding the minimum number of probiotic cells neces-
sary to ingest to get a significant effect on the different 
categories of consumers. However, despite the great 
variability, both in the literature and in practice, this 
number refers to “recommended” values [39]. 
Therefore, the technological problems related to these 
functional foods are focused on the preservation of cell 
viability during their production and their storage. 
Among the technologies that were developed to prolong 
the cells life, a good example is the microencapsulation 
in protective matrices [40,41]. 
Combining prebiotics and probiotics in one type of 
food a “synbiotic food” is obtained, the expected benefit 
of which is to improve both the survival of bacterial 
strains in the upper gastrointestinal tract and the adhesion 
of such microorganisms in the colon [42-44]. 
The quality of scientific data behind the claims attrib-
uted to the pro and prebiotics is variable and probably 
lower than expected, largely because of a lack of studies 
and a poor definition of the microorganisms and ingre-
dients used in the clinical and biological trials. 
In light of recent information, suggesting that the gut 
bacterial flora may be involved in the development of 
obesity and metabolic syndrome, the marketplace of 
functional products aimed at improving the gut environ-
ment is intended, however, to grow. In fact, some studies 
have shown that these diseases are associated to pro-
found microbioma alterations. The induction of meta-
bolic syndrome by faecal transplants reinforces the im-
portance of gut flora in the pathogenesis of this disease. 
However, much of the knowledge in this area is based on 
studies in animals, therefore, their biological significance 
requires further studies to be performed in humans [32, 
45]. 
5.2. Glucose Metabolism 
Observational studies have shown that the glycemic in-
dex (GI), an indicator of the carbohydrates ability to raise 
blood sugar, is directly associated with the risk of devel-
oping T2DM [46,47] and coronary artery disease [48]. 
Therefore, low-GI foods can be considered as a class of 
functional foods with protective effects against both the 
T2DM and the coronary heart disease. 
Several factors can contribute to reducing the GI of 
foods rich in carbohydrates, first of all the content of 
viscous fiber and prebiotics (inulin, FOS etc.), the type of 
starch (ratio of amylose/amylopectin, Resistant Starch), 
the physical structure of the food and the type of leaven-
ing [49]. 
The oat is, among the cereals, the richer in β-glucan, 
which is a highly viscous soluble fiber, capable of re-
ducing the influence of the food on postprandial glucose 
with beneficial effects on glucose metabolism [50]. This 
effect is related to some characteristics of soluble fibers 
and, among them, the viscosity surely plays a significant 
role. In fact, by slowing the gastric emptying, the diges-
tion and the absorption of nutrients in the intestine, it 
limits the increase of postprandial glucose levels. The 
enrichment of breakfast cereals with fractions of oat fiber, 
obtained by an extrusion process, has been shown to re-
duce the glycemic response from 33% to 62% in type 2 
diabetic patients [51]. 
The addition of β-glucan or other viscous fibers in 
food products has, therefore, become a common practice 
in the food industry, as it can broaden the range of low 
GI foods on the marketplace. Foods particularly rich in 
fiber, however, are not very palatable and, moreover, 
more viscous is the fiber less palatable the food is. 
Therefore, the addition of viscous fiber cannot exceed a 
certain threshold. 
Another way to reduce the food GI, without interfering 
with the palatability, is the partial replacement of glucose 
with fructose, which has a GI of 29% compared to glu-
cose, the GI of which is 84%. However, even such a re-
placement should be done in moderation, because the 
fructose in high doses has detrimental effects on lipid 
metabolism, since it increases both the levels of triglyc-
erides and low density lipoprotein cholesterol (LDLc) 
[52]. The simultaneous approaches described above, that 
is the increase of β-glucan amount and the substitution of 
sucrose with fructose, allow to reduce the GI value of a 
food product of about 40%, which is a clinically signifi-
cant effect [53]. 
This example shows how, acting on the amount of one 
or more ingredients, it is possible to produce a functional 
food with beneficial properties on glucose and insulin 
metabolism and with a palatability accepted by the con-
sumer in a daily diet. 
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The importance of the physical structure of a food in 
determining GI is largely demonstrated by one of our 
studies, the aim of which was the evaluation of the GI of 
the potato dumplings with respect to that of bread and 
other leavened foods made by wheat flour, such as pizza 
and toast bread [57]. Potato dumplings give rise to a gly-
cemic response of 30% lower than that of white bread, 
toasted bread and pizza, at the same carbohydrate content, 
fiber, resistant starch and viscosity. The lower potato 
dumplings GI is attributable to the different physical 
structure of that type of food. In fact, at electron micros-
copy white bread and other leavened foods present a 
structure rich in vacuoles, in which the starch granules 
are surrounded by gas bubbles and, therefore, easily ac-
cessible to amylases. On the contrary, potato dumplings 
structure appears compact, with the starch granules 
closely linked to the proteins and, then, less reachable by 
amylolytic enzymes (Figure 1) [57]. 
Another strategy to reduce the foods GI is to use tech-
nologies capable of modifying the starch digestibility, 
such as that employed to produce the parboiled rice (Ta-
ble 2). This technology involves a treatment of the rice 
grains with steam at high pressure. This process is able to 
lead to the formation of an outer layer of retrograded 
starch, also known as resistant starch, that is capable of 
resisting to the hydrolysis by amylases of the human gut 
and of not increasing the blood sugar level [54]. There-
fore, the parboiled rice has a lower GI compared to su-
perfine rice [55]. In the case of pasta, instead, the GI is 
about 35% - 40% lower than that of white bread, because 
of the extrusion process which is applied to the mixtures. 
The extrusion, in fact, is able to structure the proteins of 
the dough (gliadin) in a network, which is insoluble in 
water. In the mesh of this network the starch is incorpo-
rated making it less accessible to the hydrolysis by the 
gut amylases. This fact slows down the digestion and 
lowers the GI (Table 2) [56]. 
The production of bread by acid leavening (realized 
with starter such as Lactobacillus plantarum P1, L. and L. 
 
White bread Potato dumplings
Pizza Toast
 
Figure 1. Electron microscopy: Physical structure of four different glycemic index foods 57. 
 
Table 2. Examples of technological processes able to modify the starch digestibility. 
Food Technological Process 
Parboiled Rice Treatment of the whole grain rice with steam at high pressure leads to the formation of retrograded starch, known as resistant starch. 
Spaghetti The extrusion of the dough is able to structure proteins (gliadins) in a protein network insoluble in water, in which the starch is incorporated and less accessible to hydrolysis. 
Sourdough Bread 
Use of starters such as Lactobacillus plantarum P1, L. plantarum DC400, L. brevis P2, etc. 
The fermentation of lactic acid bacteria produces organic acids (lactic and acetic acids) that lower the pH of the dough, increase 
the formation of resistant starch and, in parallel, slow hydrolysis of starch. 
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plantarum DC400 brevis P2 rather than Saccharomyces 
cerevisiae) is another process used for the GI reduction. 
In this case, the fermentation of the lactic acid bacteria 
produces organic acids (lactic and acetic acids) that low-
ers the pH of dough and increases the formation of resis-
tant starch, with a consequent decrease of the GI [58]. If 
the acid leavening fermentation is associated with the use 
of a flour enriched with β-glucan, it is possible to obtain 
a bread with a GI further reduced, compared to that of a 
conventional leavening bread, prepared without the addi-
tion of viscose fiber. In fact, the addition of β-glucan 
contributes, together with the viscosity, to further slow-
down the starch hydrolysis [58]. In addition, both the 
rheological characteristics of this type of bread, such as 
volume, mass and structure and the sensory properties, 
are almost all enhanced against those of conventional 
bread [58]. Since in most European countries bread is the 
main source of carbohydrates, the inclusion of bread with 
a lower GI in a daily diet presents undoubted metabolic 
advantages in a population strategy aimed at the T2DM 
and CVD prevention. 
This type of processes which do not add, not remove 
nor replace a component with another with functional 
properties do not lead to the production of functional 
foods in sensu strictu. 
However, in terms of health impact, these processes, 
by reducing the GI of foods, exert substantial benefits in 
both the prevention and therapy of T2DM. 
For what concerns the soluble fiber used to produce 
functional foods it is to underline that, despite several 
scientific indications support the viscous fibers ability of 
reducing foods GI and, then, the risk of developing CVD, 
the FDA has recognized a “Health Claim” to the fiber of 
oats and psyllium not for the benefits on blood glucose, 
but only for their demonstrated capability of reducing 
cholesterol plasma levels [59]. Therefore, it is crucial to 
produce further scientific data to support the capability of 
viscous fibers of improving not only the lipid metabolism, 
but also the glucose and insulin metabolism. On the other 
hand, researchers should co-operate with industry, in 
order to make it to invest in new biotechnology for the 
production of different types of low GI functional foods, 
with better acceptability by the consumers.  
5.3. Lipid Metabolism 
It is widely known that in diabetic patient the risk for 
CVD is 2 - 4 times higher than the general population 
[60]. This higher risk is not justified only by high plasma 
glucose levels but also by association with high plasma 
cholesterol concentrations. Therefore, the management of 
diabetes needs to control either blood glucose and lipid 
metabolism. In clinical practice, pharmacological inter-
vention with statins has been demonstrated to be suc-
cessful in reducing blood cholesterol and cardiovascular 
mortality. But we must consider that treatment with stat-
ins have also some disadvantages: 1) statins have a cost 
for the National Health Service and are provided free of 
charge only to those subjects presenting a CVD high risk, 
2) they are drugs and so, in addition to having beneficial 
effects, also cause drawback side effects that contraindi-
cate their use in some individuals, and 3) treatment with 
statins could be insufficient alone to control cholesterol. 
However, several components of foods are able to reduce 
plasma cholesterol levels. The National Cholesterol 
Education Program (NCEP) Expert Panel for the treat-
ment of hypercholesterolemia advices not only to limit 
the diet intake of saturated fats and cholesterol, but also 
to increase the consumption of viscous fiber and phytos-
terols, because of their lipid-lowering action [61]. Be-
sides viscous fiber (contained in oats, barley and psyl-
lium) and phytosterols, also soy proteins and nuts have a 
proven cholesterol-lowering effect [62]. The literature 
reports that each of these components reduces the levels 
of LDLc from 2% to 20% but, in clinical practice, it is 
likely that the magnitude of the effect can be lower, equal 
to 3% - 7%. However, the simultaneous presence of all 
these components in the same diet, thanks to a synergis-
tic action, can make the cholesterol lowering effect much 
greater and clinically relevant. A reduction in LDLc by 
about 22.5% has been estimated to be achieved if, in the 
same diet, the consumption of viscous fiber, plant sterols 
(fortified margarine), soy proteins (e.g. soy milk, tofu 
etc.) and nuts is combined [62].  
The simultaneous use of these functional components 
is particularly interesting, because in this case the ob-
tained cholesterol lowering effect is additive, since each 
component acts by a different mechanism. The viscous 
fiber increases the loss of bile, the phytosterols reduce 
the absorption of dietary cholesterol, soy proteins tend to 
inhibit the synthesis of cholesterol and Apo B and nuts 
act by a combination of these mechanisms. The effec-
tiveness of this type of diet on the reduction of LDLc is 
equivalent to that obtained by associating a treatment 
with 20 mg/day of lovastatin to a low fat diet (recom-
mended by the NCEP- Adult Treatment Panel III) [63]. It 
should be noted that the cholesterol lowering effect of 
this type of diet based on functional foods also shows the 
advantage of reducing the C-reactive protein (CRP) 
plasma concentrations, another cardiovascular risk factor 
[63].  
One of the limitations of some functional foods is, 
however, the low palatability, that, associated with the 
lack of variety, prevents optimal compliance to diet. The 
side effects are, instead, scarce. The larger volume of the 
products rich in fiber can be a problem, but it can also 
offer the big advantage of limiting the energy intake in 
overweight/obese. Furthermore, in some cases, flatulence 
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induced by the ingestion of these foods limits their con-
sumption making them less attractive. 
In any case, based on this evidence, the FDA has ex-
tended the Health Claim of cardiovascular protection 
conferred to the viscous fibers also to phytosterols, soy 
and nuts [64,65]. However, other authorities, who have 
expertise in this area, have not yet expressed an explicit 
opinion about the use of functional foods or about food 
components with cholesterol-lowering properties. 
6. Conclusions 
Functional foods, consumed in a context of a mixed diet 
and a healthy lifestyle, can represent an additional op-
portunity for T2DM and CVD prevention for general 
population, while for those with clinical disease, this type 
of foods can help in controlling the metabolic alterations 
thereto associated. However, before recommending the 
use of functional foods, a nutritional assessment, which 
demonstrates the health benefit or that the risk reduction 
of diseases resulting from their use is clinically relevant, 
well tolerated and free of side effects, is required. In fact, 
among all the functional foods available on the market-
place, to date only a few of them have obtained the 
statement of a “Health Claim”. This is due to the fact that, 
in most cases, there is not any scientific evidence based 
on human intervention studies that justify a “Health 
Claim”. In other cases, instead, the available data are not 
consistent with the proposed claims. 
In order to encourage the competent authorities to cer-
tify the Health Claim of a food, it is of primary impor-
tance to make “ad hoc”, controlled and randomized 
clinical trials, which unequivocally demonstrate the ef-
fectiveness of a particular food component in improving 
of a biological function or in the prevention of any dis-
ease. 
On the other hand, functional foods are also a chal-
lenge for the food industry, which is called upon to im-
plement and/or develop new technologies useful for the 
creation of new foods, which, besides enhanced health 
properties, also have better organoleptic properties suit-
able to be consumed in a daily diet. 
Finally, consumer education to functional foods con-
sumption should be supported by adequate information, 
able to dispel prejudices about processed food, usually 
negatively perceived by the consumer when compared to 
the natural ones. 
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